Cargando…

NAFLD and cardiovascular disease

Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic hepatic disease and liver transplant in Western societies. The increasing prevalence is related to dietary changes and sedentarism and follows the increasing frequency of obesity and type 2 diabetes mellitus. Growing evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Martins, Elisabete, Oliveira, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726310/
https://www.ncbi.nlm.nih.gov/pubmed/31595238
http://dx.doi.org/10.1016/j.pbj.0000000000000002
_version_ 1783449077706391552
author Martins, Elisabete
Oliveira, Ana
author_facet Martins, Elisabete
Oliveira, Ana
author_sort Martins, Elisabete
collection PubMed
description Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic hepatic disease and liver transplant in Western societies. The increasing prevalence is related to dietary changes and sedentarism and follows the increasing frequency of obesity and type 2 diabetes mellitus. Growing evidence of association of NAFLD with cardiovascular diseases (CVD), independent of cardiovascular risk factors, has prompted the clarification of whether the liver is mainly a key-effector or a target-organ of the metabolic disarrangements in the metabolic syndrome. The therapeutic strategies able to alter liver disease progression and, through this, reduce the cardiovascular risk have also been tested in the last 2 decades. This review focus on the possible interactions between hepatic disease, metabolic syndrome, and CVD, and on their implications for clinical practice.
format Online
Article
Text
id pubmed-6726310
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-67263102019-10-08 NAFLD and cardiovascular disease Martins, Elisabete Oliveira, Ana Porto Biomed J Original Article Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic hepatic disease and liver transplant in Western societies. The increasing prevalence is related to dietary changes and sedentarism and follows the increasing frequency of obesity and type 2 diabetes mellitus. Growing evidence of association of NAFLD with cardiovascular diseases (CVD), independent of cardiovascular risk factors, has prompted the clarification of whether the liver is mainly a key-effector or a target-organ of the metabolic disarrangements in the metabolic syndrome. The therapeutic strategies able to alter liver disease progression and, through this, reduce the cardiovascular risk have also been tested in the last 2 decades. This review focus on the possible interactions between hepatic disease, metabolic syndrome, and CVD, and on their implications for clinical practice. 2018-07-18 /pmc/articles/PMC6726310/ /pubmed/31595238 http://dx.doi.org/10.1016/j.pbj.0000000000000002 Text en Copyright © 2018 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of PBJ-Associação Porto Biomedical/Porto Biomedical Society. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Original Article
Martins, Elisabete
Oliveira, Ana
NAFLD and cardiovascular disease
title NAFLD and cardiovascular disease
title_full NAFLD and cardiovascular disease
title_fullStr NAFLD and cardiovascular disease
title_full_unstemmed NAFLD and cardiovascular disease
title_short NAFLD and cardiovascular disease
title_sort nafld and cardiovascular disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726310/
https://www.ncbi.nlm.nih.gov/pubmed/31595238
http://dx.doi.org/10.1016/j.pbj.0000000000000002
work_keys_str_mv AT martinselisabete nafldandcardiovasculardisease
AT oliveiraana nafldandcardiovasculardisease